Neurocysticercosis in children

Symposium on Neurological Disorder-Advances in Management-II

Abstract

Neurocysticercosis (NCC) is a common cause of seizures and neurologic disease. Although there may be variable presentations depending on the stage and location of cysts in the nervous system, most children (> 80%) present with seizures particularly partial seizures. About a third of cases have headache and vomiting. Diagnosis is made by either CT or MRI. Single enhancing lesions are the commonest visualization of a scolex confirms the diagnosis. Some cases have multiple cysts with a characterstic starry-sky appearance. Management involves use of anticonvulsants for seizures and steroids for cerebral edema. The use of cysticidal therapy continues to be debated. Controlled studies have shown that cysticidal therapy helps in increased and faster resolution of CT lesions. Improvement in long - term seizure control has not yet been proven. Children with single lesions have a good outcome and seizure recurrence rate is low. Children with multiple lesions have recurrent seizures. Extraparenchymal NCC has a guarded prognosis but it is rare in children. In endemic areas NCC must be considered in the differential diagnosis of seizures and various other neurological disorders.

Key words

Neurocysticercosis (NCC) Seizures Cysts Diagnosis Management 

References

  1. 1.
    White AC. Neurocysticercosis: A major cause of neurological disease worldwide. Clin Infect Dis 1997; 24: 101–115.PubMedCrossRefGoogle Scholar
  2. 2.
    Roman G, Sotelo J, Del Brutto O et al. A proposal to declare neurocysticercosis an international reportable disease. Bull World Health Organ 2000; 78: 399–406.PubMedGoogle Scholar
  3. 3.
    Commission on Tropical Diseases of the International League Against Epilepsy. Relationship between Epilepsy and tropical diseases. Epilepsia 1994; 35: 89–93.CrossRefGoogle Scholar
  4. 4.
    Singhi S, Singhi P. Clinical profile and etiology of partial seizures in North Indian Infants and children. J Epilepsy 1997; 10: 32–36.CrossRefGoogle Scholar
  5. 5.
    Leid RW, Suquet CM, Tanigoshi L. Parasite defense mechanisms for evasion of host attack: a review. Vet Parasitol 1987; 25: 147–162.PubMedCrossRefGoogle Scholar
  6. 6.
    Escobar A. The pathology of neurocysticercosis. In Palacios E, Rodriguez-Carbajal KJ, Taveras J, eds. Cysticercosis of the central nervous system. Illinois: Springfield, Charles C Thomas, 1983; 27–54.Google Scholar
  7. 7.
    Thussu A, Sehgal S, Sharma M, Lal V, Sawhney IMS, Prabhakar S. Comparison of cellular responses in single and multiple lesions neurocysticercosis. Ann Trop Med Parasitol 1997; 91: 627–632.PubMedCrossRefGoogle Scholar
  8. 8.
    Singhi P, Ray M, Singhi S, Khandelwal N. Clinical spectrum of 500 children with neurocysticercosis and response to albendazole therapy. J Child Neurol 2000; 15: 207–213.PubMedCrossRefGoogle Scholar
  9. 9.
    Talukdar B, Saxena A, Popli VK, Choudhury V. Neurocysticercosis in children: clinical characteristics and outcome. Annals Trop Pediatr 2002; 22: 333–339.CrossRefGoogle Scholar
  10. 10.
    Morales NM, Agapejev S, Morales RR, Padula NA, Lima MM. Clinical aspects of neurocysticercosis in children. Pediatr Neurol 2000; 22: 287–291.PubMedCrossRefGoogle Scholar
  11. 11.
    Singh G, Singh P. Singh I, Rani A, Kaushal S, Avasthi G. Epidemiologic classification of seizures associated with neurocysticercosis: observations from a sample of seizures disorders in neurologic care in India. Acta Neurol Scand 2006; 113: 233–240.PubMedCrossRefGoogle Scholar
  12. 12.
    Prasad A, Gupta RK, Pradhan S, Tripathi M, Pandey CM, Prasad KN. What triggers seizures in neurocysticercosis? A MRI- based study in pig farming community from a district of North India. Parasitol Int 2008; 57: 166–171.PubMedCrossRefGoogle Scholar
  13. 13.
    Wichert-Ana L, Velasco TR, Terra-Bustamante VC et al. Surgical treatment for mesial temporal lobe epilepsy in the presence of massive calcified neurocysticercosis. Arch Neurol 2004; 61: 1117–1119.PubMedCrossRefGoogle Scholar
  14. 14.
    Del Brutto OH, Santibanez R, Noboa CA et al. Epilepsy due to neurocysticercosis: Analysis of 203 patients. Neurology 1992; 42: 389–392.PubMedGoogle Scholar
  15. 15.
    Del Brutto OH. Cysticercosis and cerebrovascular disease: a review. J Neurol Neurosurg Psychiatry 1992; 55: 252–254.PubMedCrossRefGoogle Scholar
  16. 16.
    Forlenza OV, Filho AH, Nobrega JP et al. Psychiatry manifestations of neurocysticercosis; a study of 38 patients from a neurology clinic in Brazil. J Neurol Neurosurg Psychiatry 1997; 85: 612–616.CrossRefGoogle Scholar
  17. 17.
    Singhi PD., Baranwal AK. Single small enhancing computed tomographic lesion in Indian children-I: Evolution of current concepts. J Trop Pediatr 2001; 47: 204–207.PubMedCrossRefGoogle Scholar
  18. 18.
    Antoniuk SA, Bruck I, Dos Santos LH et al. Seizures associated with calcifications and edema in neurocysticercosis. Pediatr Neurol 2001; 25: 309–311.PubMedCrossRefGoogle Scholar
  19. 19.
    Sotelo J. Which MRI sequences are best suited to the evaluation of patients with neurocysticercosis? Nat Clin Pract Neurol 2008; 4: 72–73.PubMedCrossRefGoogle Scholar
  20. 20.
    Garcia HH, Del Brutto OH. Imaging findings in neurocysticercosis. Acta Trop 2003; 87: 71–78.PubMedGoogle Scholar
  21. 21.
    Jayasundar R, Singh VP, RaghunathanP, Jain K, Banerji AK. Inflammatory granulomas: evaluation with proton MRS. NMR Biomed 1999; 12: 139–144.PubMedCrossRefGoogle Scholar
  22. 22.
    Govindappa SS, Narayanan JP, Krishnamoorthy VM, Shastry CH, Balasubramaniam A, Krishna SS. Improved detection of intraventricular cysticercal cysts with the use of three-dimensional constructive interference in steady state MR sequences. Am J Neuroradiol 2000; 21: 679–684.PubMedGoogle Scholar
  23. 23.
    Gupta RK, Prakash M, Mishra AM, Husain M, Prasad KN, Husain N. Role of diffusion weighted imaging in differentiation of intracranial tuberculoma and tuberculous abscess from cysticercus granulomas-a report of more than 100 lesions. Eur J Radiol 2005; 55: 384–392.PubMedCrossRefGoogle Scholar
  24. 24.
    Rosas N, Sotelo J, Neito D. ELISA in the diagnosis of neurocysticercosis. Arch Neurol 1986; 43: 353–356.PubMedGoogle Scholar
  25. 25.
    Wilson M, Bryan RT, Fried JA et al. Clinical evaluation of the cysticercosis enzyme linked immunoelectrotransfer blot in patients with neurocysticercosis. J Infect Dis 1991; 164: 1007–1009.PubMedGoogle Scholar
  26. 26.
    Mandal J, Singhi PD, Khandelwal N, Malla N. Evaluation of ELISA and dot blots for the serodiagnosis of neurocysticercosis, in children found to have single or multiple enhancing lesions in computerized tomographic scans of the brain. Ann Trop Med Parasitol 2006; 100: 39–48.PubMedCrossRefGoogle Scholar
  27. 27.
    Rodriguez-Canul R, Allan JC, Fletes C et al. Comparative evaluation of purified Taenia solium glycoproteins and crude metacestode extracts by immunoblot for the serodiagnosis of human Taenia Solium cysticercosis. J Clin Diagnostic Lab Immunol.Google Scholar
  28. 28.
    Mandal J, Singhi PD, Khandelwal N, Malla N. Evaluation of lower molecular mass (20-24 kDa) Taenia solium cysticercus antigen fraction by ELISA and dot blot for the serodiagnosis of neurocysticercosis in children. Parasitol Res 2008; 102: 1097–1101.PubMedCrossRefGoogle Scholar
  29. 29.
    Del Brutto OH, Wadia NH, Dumas M et al. Proposal of diagnostic criteria for human cysticercosis and neurocysticercosis. J Neurol Sci 1996; 142: 1–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Del Brutto OH, Rajshekhar V, White AC et al. Proposed diagnostic criteria for neurocysticercosis. Neurology 2001; 57: 177–183.PubMedGoogle Scholar
  31. 31.
    Rajshekhar V, Haran RP, Prakash S, Chandy MJ. Differentiating solitary small cysticercus grandulomas and tuberculomas in patients with epilepsy- clinical and computerized tomographic criteria. J Neurosurgery 1993; 78: 402–407.CrossRefGoogle Scholar
  32. 32.
    Baranwal AK, Singhi P, Singhi S, Khandelwal N. Seizure recurrence in children with focal seizures and single small enhancing computed tomographic lesions. Prognostic Factors on Long-Term follow-Up. J Child Neurol 2001;16: 443–445.PubMedCrossRefGoogle Scholar
  33. 33.
    Ferreira LS, Zanardi VA, Scotoni AE, Li LM, Guerreiro MM. Childhood epilepsy due to neurocysticercosis: a comparative study. Epilepsia 2001, 42: 1438–1444.PubMedCrossRefGoogle Scholar
  34. 34.
    Del Brutto AH. Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis. Neurology 1994; 44: 1706–1709.PubMedGoogle Scholar
  35. 35.
    Garcia H H, Carlton A, W Evans, Nash TE et al. Current Consensus Guidelines for Treatment of neurocysticercosis. Clinical Microbiology Reviews 2002; 15: 747–756.PubMedCrossRefGoogle Scholar
  36. 36.
    Singhi P, Dinakaran, Khandelwal NK. One year versus two years of antiepileptic therapy for SSECTL. J Trop. Pediatr 2003; 5: 274–278.CrossRefGoogle Scholar
  37. 37.
    Singhi PD. Concomitant steroid and albendazole for treating neurocysticercosis. Indian Pediatr 1999; 36: 1176.Google Scholar
  38. 38.
    Sotelo J, Torres B, Rubio-Donnadieu F, Escobedo F, Rodriquez-Carbajal J. Praziquantel in the treatment of neurocysticercosis: long term follow-up. Neurology 1985; 35: 752–754.PubMedGoogle Scholar
  39. 39.
    Escobedo F, Penagos P, Rodriquez J. Sotelo J. Albendazole therapy for neurocysticercosis. Arch Intern Med 1987; 147: 738–741.PubMedCrossRefGoogle Scholar
  40. 40.
    Cruz M, Cruz L, Horton J. Albendazole vs praziquantel in the treatment of cerebral cysticercosis: clinical evaluation Trans R Soc Trop Med Hyg 1991; 85: 244–247.PubMedCrossRefGoogle Scholar
  41. 41.
    Takayanaqui OM, Jardim E. Therapy for neurocysticercosis: comparison between albendazole and praziquantel. Arch Neurol 1992; 49: 290–294.Google Scholar
  42. 42.
    Baranwal AK, Singhi PD, Khandelwal N, Singhi SC. Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized placebo- controlled, double blind trial. Pediatr Infect Dis J 1998; 17: 696–700.PubMedCrossRefGoogle Scholar
  43. 43.
    Kalra V, Dua T, Kumar V. Efficacy of albendazole and short-course dexamethasone treatment in children with 1 or 2 ring-enhancing lesions of neurocysticercosis: a randomized controlled trial. J Pediatr 2003; 143: 111–114.PubMedGoogle Scholar
  44. 44.
    Thussu A, Chattopadhyay A, Sawhney IM, Khandelwal N. Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy. J Neurol Neurosurg Psychiatry 2008; 79: 238–239.CrossRefGoogle Scholar
  45. 45.
    Carpio A, Kelvin EA, Bagiella E, Leslie D, Leon P, Andrews H et al. Ecuadorian Neurocysticercosis Group. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2008; 79:1050–1055.PubMedCrossRefGoogle Scholar
  46. 46.
    Padma MV, Behari M, Misra NK, Ahuja N. Albendazole in single CT ring lesions in epilepsy. Neurology 1994; 44: 1344–1346.PubMedGoogle Scholar
  47. 47.
    Salinas R, Counsell C, Prasad K, Gelband H, Garner P. Treating neurocysticercosis medically: a systematic review of randomized, controlled trials. Trop Med Int Health 1999; 4: 713–718.PubMedCrossRefGoogle Scholar
  48. 48.
    Salinas R, Prasad K. Drugs for treating neurocysticercosis (tapeworm infection of the brain). Cochrane Database Syst Rev 2007; CD000215.Google Scholar
  49. 49.
    Del Brutto OH, Roos KL, Coffey CS, García HH. Metaanalysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med 2006 4;145:43–51.Google Scholar
  50. 50.
    Medina MT, Genton P, Montoya MC et al. Effect of anticysticercal treatment on the prognosis of epilepsy in neurocysticercosis: a pilot trial. Epilepsia 1993; 34: 1024–1027.PubMedCrossRefGoogle Scholar
  51. 51.
    Vazquez V, Sotelo J. The course of seizures after treatment for cerebral cysticercosis. N Engl J Med 1992; 327: 696–701.PubMedGoogle Scholar
  52. 52.
    Del Brutto OH. The use of albendazole in patients with single lesions enhanced on contrast CT. N Engl J Med 1993; 328: 356–357.PubMedCrossRefGoogle Scholar
  53. 53.
    Garcia HH, Gilman RH, Martinez SM, Moulton LH, Del Brutto OH et al. Cysticercosis Working Group in Peru. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 2004; 15;350:249–258.Google Scholar
  54. 54.
    Das K, Mondal GP, Banerjee M, Mukherjee BB, Singh OP.Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study. J Clin Neurosci 2007; 14: 1172–1177.PubMedCrossRefGoogle Scholar
  55. 55.
    Jung H, Hurtado M, Medina MT, Sanchez M, Sotelo J. Dexamethasone increases plasma levels of albendazole. J Neurol 1990; 237: 279–280.PubMedCrossRefGoogle Scholar
  56. 56.
    Vazquez ML, Jung H, Sotelo J. Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. Neurology 1987; 37: 1561–1562.PubMedGoogle Scholar
  57. 57.
    Bittencourt PR, Gracia CM, Martins R et al. Phenytoin and carbamazepine decreased oral bioavailability of praziquantel. Neurology 1992; 42: 492–496.PubMedGoogle Scholar
  58. 58.
    Singhi P, Dayal Devi, Khandelwal N. One week versus four weeks of albendazole therapy for neurocysticercosis in children: a randomized placebo controlled double blind trial. Pediatr Infect Dis J 2003; 22: 268–272.PubMedCrossRefGoogle Scholar
  59. 59.
    Corral I, Quereda C, Moreno A et al. Intramedullay cysticercosis cured with drug treatment. A case report. Spine 1996; 21: 2284–2287.PubMedCrossRefGoogle Scholar
  60. 60.
    Del Brutto OH, Sotelo J, Aquirre R, Diaz Calderon E, Alarcon TA. Albendazole therapy for giant subarachnoid cysticerci. Arch Neurol 1992; 49: 535–538.PubMedGoogle Scholar
  61. 61.
    Proano JV, Madrazo I, Avelar F et al. Medical treatment for neurocysticercosis characterized by giant subarachnoid cysts. N Engl J Med 2001; 345: 879–885.PubMedCrossRefGoogle Scholar
  62. 62.
    Pretell EJ, Garcia HH, Custodio N et al. Short regimen of praziquantel in the treatment of single brain enhancing lesions. Clin Neurol Neurosurg 2000, 102: 215–218.PubMedCrossRefGoogle Scholar
  63. 63.
    Lopez-Gomez M, Castro N, Jung H, Sotelo J, Corona T. Optimization of the single -day praziquantel therapy for neurocysticercosis. Neurology 2001; 57: 1929–1930.PubMedGoogle Scholar
  64. 64.
    Kaur S, Singhi P, Singhi S, Khandelwal N. Combination Therapy of Praziquantal and Albandazole worries Albandazole alone in Children with single Lesion NCC-a randomized placebo controlled double blind trial Ped Infect Dis J 2008 - In Press.Google Scholar
  65. 65.
    Nash TE, Singh G, White AG et al. Treatment of neurocysticercosis: current status and future research needs. Neurology 2006; 67: 1120–1127PubMedCrossRefGoogle Scholar
  66. 66.
    Suri A, Goel RK, Ahmad FU, Vellimana AK, Sharma BS, Mahapatra AK. Transventricular, transaqueductal scopein-scope endoscopic excision of fourth ventricular neurocysticercosis: a series of 13 cases and a review. L Neurosurg Pedaitrics 2008;1:35–39.CrossRefGoogle Scholar
  67. 67.
    Goel RK, Ahmad FU, Vellimana AK et al. Endoscopic management of intraventricular neurocysticercosis. J Clin Neurosci 2008 Jul 22. [Epub ahead of print] Google Scholar
  68. 68.
    Singhi PD, Baranwal AK. Single small enhancing computed tomographic lesions in Indian children-II. Clinical features, pathology, radiology and management. J Trop Pediatr 2001; 47: 266–270.PubMedCrossRefGoogle Scholar
  69. 69.
    Jain S, Padma MV, Kanga U, Mehra NK, Maheshwari NC. Family studies and human leukocyte antigen class II typing in Indian probands with seizures in association with single small enhancing computed tomography lesions. Epilepsia 1999; 40: 232–238.PubMedCrossRefGoogle Scholar
  70. 70.
    Cruz ME, Davis A, Dixon H, Pawlowski ZS, Proano J. Operational studies on the control of Taenia solium taeniasis/cysticercosis in Ecuador. Bull WHO 1989; 67: 401–407.PubMedGoogle Scholar
  71. 71.
    Sarti E, Schantz PM, Avila G et al. Mass treatment against human taeniasis for the control of cysticercosis: a population-based intervention study. Trans R Soc Trop Med Hyg 2000; 94: 85–89.PubMedCrossRefGoogle Scholar
  72. 72.
    Gilman RH, Garcia HH. Gonzales AE et al. Metodos para controllar la transmission de la cisticercosis. In Garcia HH, Martinez S, eds. Teniasis/cisticercosis por t. Solium. Lima: Editorial Universo SA, 1996; 327–339.Google Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2009

Authors and Affiliations

  1. 1.Department of PediatricsPostgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations